Gena Wang

Why Intellia Therapeutics Stock Is Soaring Today

Barclays: Editas Medicine On Track To File New Drug App Next Year

Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug

Barclays: Editas Medicine On Track To File New Drug App Next Year

Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug

Breaking Down Barclays' New Bullish Calls On Biotech

2 Names Barclays Is Now Bearish On In Biotech

Breaking Down Barclays' New Bullish Calls On Biotech

2 Names Barclays Is Now Bearish On In Biotech

Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage

Revusiran Termination A Setback For Alnylam, But Platform-Wide Problems Unlikely

Gena Wang Recent News

Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23

Jefferies Examines The Effect Of Sarepta's Drug Approval On PTC Therapeutics

Jefferies Upgrades Editas Medicine To Buy, Positive On Partnerships & Progress On LCA 10 IND Testing

Sarepta Shares Under Pressure As Jefferies Downgrades To Underperform

PTC Therapeutics: Oppenheimer Bull Cuts Target From $111 To $39; Jefferies Less Certain on Translarna

Jefferies Upgrades PTC Therapeutics To Hold; Sees FDA Approvalability Priced In And Is Uncertain On EU Decision

Leerink: Pharmacyclics Is Now Worth $240

Why OvaScience Shares Soared 35%